A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study
Figure 1
Patient disposition (all enrolled patients). *Except for one, none of the deaths were suspected to be related to the study treatment.